Also known as: MK-0616 · Enlicitide
Enlicitide decanoate is Merck's investigational oral PCSK9 inhibitor — a macrocyclic peptide engineered to deliver antibody-like target engagement in a daily pill. In the Phase 3 CORALreef programme it cut LDL cholesterol by 55.8% in hypercholesterolaemia and 59.4% in heterozygous familial hypercholesterolaemia. If approved it would be the first oral PCSK9 inhibitor.
Every PCSK9 inhibitor on the market is an injectable monoclonal antibody. Enlicitide is the attempt to reach the same validated target orally, using a macrocyclic peptide — a constrained ring structure that resists gut proteolysis well enough to survive oral administration while retaining antibody-like binding specificity.
Across the Phase 3 CORALreef trials it met its primary and key secondary endpoints, with adverse events comparable to placebo and low discontinuation. A cardiovascular outcomes trial (CORALreef Outcomes) is running — the study that determines whether the LDL reduction translates into fewer cardiac events. Not yet approved.
PCSK9 binds the hepatic LDL receptor and marks it for degradation, so less LDL is cleared from the blood. Enlicitide binds PCSK9 and blocks that interaction, leaving more LDL receptors on the hepatocyte surface and increasing clearance of circulating LDL cholesterol.
The macrocyclic scaffold is the differentiator: cyclisation confers the protease resistance and membrane permeability that a conventional linear peptide of this size would lack, which is what makes oral dosing of a PCSK9 binder feasible at all.
Investigational. Its significance is delivery rather than target: PCSK9 inhibition is already validated by injectable antibodies, and enlicitide is the attempt to achieve it in a daily pill. The cardiovascular outcomes trial is the one that determines whether LDL lowering translates to fewer cardiac events.
Lipid-lowering therapy is a long-term intervention, not a cycled one. Stopping reverses the effect.
Investigational — not approved. Do not substitute for prescribed lipid therapy.
Investigational, Phase 3 (CORALreef programme); cardiovascular outcomes trial ongoing. As a macrocyclic peptide it has no conventional linear sequence. Molecular weight derived from the published formula (1722.12), matching the published value.
Ask anything about Enlicitide Decanoate — mechanisms, dosing protocols, interactions, or research comparisons.
Angiotensin 1-7 is an endogenous heptapeptide of the renin-angiotensin system (RAS), produced primarily by ACE2 cleavage…
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide developed by Hazel Szeto and Peter Schiller at Weill Cornel…